Gadoxetate Disodium

CHEMBL2103740 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
725.7 g/mol
LogP
Phase
4

This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.

الوزن الجزيئي

725,7000 g/mol

TPSA

220,00 Ų

المجالات العلاجية

آلية العمل

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Gd+3]

InChI

InChI=1S/C23H33N3O11.Gd.2Na/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;;;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);;;/q;+3;2*+1/p-5

Molecular Formula

C23H28GdN3Na2O11

HBD / HBA

- / 14

الروابط القابلة للدوران

4

الذرات الثقيلة

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Gadoxetate Disodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103740. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 91754427. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.